<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Solitary extramedullary plasmacytoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Solitary extramedullary plasmacytoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Solitary extramedullary plasmacytoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">María-Victoria Mateos, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Plasma cell neoplasms (plasma cell dyscrasias) are a group of entities characterized by the neoplastic proliferation of clonal plasma cells, typically producing a monoclonal immunoglobulin. Plasma cell neoplasms can present as a single lesion (solitary plasmacytoma) or as multiple lesions (multiple myeloma). Solitary plasmacytomas most frequently occur in bone (plasmacytoma of bone), but can also be found outside bone in soft tissues (extramedullary plasmacytoma) [<a href="#rid1">1-4</a>]. Why some patients develop multiple myeloma and others a single plasmacytoma is not understood, but it might be related to differences in cellular adhesion molecules or chemokine receptor expression profiles of the malignant plasma cells [<a href="#rid5">5</a>].</p><p>Solitary extramedullary plasmacytomas (SEP; solitary extraosseous plasmacytoma) are plasma cell tumors that arise outside of the bone marrow. They are solitary lesions and are most often located in the head and neck region, mainly in the upper aerodigestive tract, but may also occur in the gastrointestinal (GI) tract, urinary bladder, central nervous system, thyroid, breast, testes, parotid gland, lymph nodes, and skin.</p><p>SEP refers to a solitary non-osseus plasma cell neoplasm in the absence of any other sign of multiple myeloma. Note that extramedullary plasmacytomas can arise in patients with multiple myeloma at any time during the course of the disease and should not be confused with SEP. The diagnosis and management of SEP will be discussed here. The diagnosis and treatment of other plasma cell disorders (eg, solitary plasmacytoma of bone, multiple myeloma, primary AL amyloidosis, monoclonal gammopathy of undetermined significance) are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6653.html" rel="external">"Solitary plasmacytoma of bone"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SEPs account for approximately 3 percent of plasma cell malignancies [<a href="#rid6">6,7</a>]. In one large population-based study from the US Surveillance, Epidemiology and End Results (SEER) program, the incidence for SEP was 0.10 per 100,000 persons per year [<a href="#rid6">6</a>]. The median age at diagnosis is 55 to 60 years, and approximately two-thirds of patients are male.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most patients present with symptoms related to the location of the mass. Approximately 45 to 80 percent involve the upper respiratory tract (ie, oronasopharynx and paranasal sinuses), producing epistaxis, nasal discharge (rhinorrhea), or nasal obstruction [<a href="#rid8">8-13</a>]. Less common sites of involvement include connective/soft tissue [<a href="#rid13">13</a>], the gastrointestinal tract [<a href="#rid14">14</a>], liver [<a href="#rid15">15</a>], lymph nodes [<a href="#rid16">16,17</a>], testes [<a href="#rid18">18</a>], skin, breast [<a href="#rid19">19</a>], and central nervous system [<a href="#rid20">20</a>]. Primary plasmacytoma of the lung often presents as a pulmonary nodule or hilar mass with or without hemoptysis [<a href="#rid21">21</a>]. Regional lymph nodes may be involved.</p><p>By definition, patients with SEP do <strong>not</strong> have any myeloma-defining events including: </p><p class="bulletIndent1"><span class="glyph">●</span>No end-organ damage attributable to the underlying plasma cell disorder – End-organ damage can manifest as anemia (ie, hemoglobin &lt;10 g/dL or 2 g/dL below normal), hypercalcemia (ie, serum calcium &gt;11.5 mg/dL [2.875 mmol/liter]), kidney impairment (ie, serum creatinine &gt;2 mg/dL [176.8 micromol/liter]), and/or additional bone or extramedullary lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No biomarkers of malignancy – Biomarkers of multiple myeloma include clonal bone marrow plasma cell ≥60 percent; involved:uninvolved serum free light chain ratio ≥100; and/or &gt;1 focal lesions on magnetic resonance imaging (MRI) studies.</p><p></p><p>Myeloma-defining events are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The evaluation of a patient with a suspected SEP should include the following studies in addition to a complete history and physical examination:</p><p class="bulletIndent1"><span class="glyph">●</span>A biopsy of the suspected lesion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood count and differential with examination of the peripheral blood smear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chemistry screen that includes measurements of serum calcium, creatinine, albumin, lactate dehydrogenase, beta-2 microglobulin, C-reactive protein, and serum free light chains (FLC) and FLC ratio. (See  <a class="medical medical_review" href="/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum protein electrophoresis (SPEP) with immunofixation and quantitation of immunoglobulins. (See  <a class="medical medical_review" href="/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A routine urinalysis, a 24-hour urine collection for electrophoresis (UPEP) and immunofixation, and a serum FLC assay. The FLC assay cannot replace the 24-hour urine collection with SPEP and immunofixation in patients with a confirmed plasma cell proliferative disorder. (See  <a class="medical medical_review" href="/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A unilateral bone marrow aspiration and biopsy with fluorescent in situ hybridization (FISH) for myeloma-related chromosomal abnormalities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cross sectional imaging with whole body combined fluorine-18-labeled fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) (<sup>18</sup>F-FDG PET/CT) scan [<a href="#rid22">22</a>]. If PET/CT is not available, whole body MRI is an acceptable alternative [<a href="#rid23">23</a>].</p><p></p><p>Spinal cord compression from an extramedullary plasmacytoma should be suspected in patients with severe back pain, weakness, or paresthesias of the lower extremities; bladder incontinence; or bowel dysfunction. MRI or CT myelography of the entire spine must be performed <strong>immediately</strong> if this complication is suspected. On MRI, extramedullary plasmacytoma is usually hypointense or isointense on T1-weighted images and isointense or hyperintense on T2-weighted images [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of an SEP requires the following  (<a class="graphic graphic_table graphicRef98065" href="/d/graphic/98065.html" rel="external">table 1</a>) [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy-proven extramedullary tumor with evidence of clonal plasma cells  (<a class="graphic graphic_picture graphicRef57085" href="/d/graphic/57085.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef93781" href="/d/graphic/93781.html" rel="external">picture 2</a>). (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Morphology and immunophenotype'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><sup>18</sup>F-FDG PET/CT must show no other lytic or extramedullary lesions (except for the primary solitary lesion). A skeletal survey is insufficient to rule out other areas of involvement, which would upstage the patient to multiple myeloma. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow aspirate and biopsy may demonstrate no clonal plasma cells (SEP) or clonal plasma cells in the bone marrow at a level &lt;10 percent (SEP with minimal marrow involvement).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no anemia, hypercalcemia, or kidney impairment that could be attributed to a clonal plasma cell proliferative disorder. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p>Some patients may have a small monoclonal protein, usually IgA, in the serum or urine, which often disappears following treatment. The involved:uninvolved serum free light chain (FLC) ratio must be &lt;100. </p><p>Some patients with a solitary extramedullary lesion may demonstrate up to 10 percent clonal plasma cells and are considered as having SEP with minimal marrow involvement [<a href="#rid25">25</a>]. These patients are treated in a similar fashion to SEP but have a higher risk of progression to symptomatic myeloma. If patients suspected to have SEP demonstrate 10 percent or more clonal plasma cells in the bone marrow, they should be considered to have multiple myeloma rather than SEP. These patients are also often treated in a similar fashion to SEP but may require additional systemic therapy. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>It is important to distinguish SEPs from other plasma cell dyscrasias for the purposes of prognosis and treatment. The main condition to consider in the differential diagnosis is multiple myeloma, but other hematologic and non-hematologic neoplasms must also be considered. </p><p>Solitary plasmacytoma can be distinguished from most neoplasms based on the morphologic appearance of plasma cells and on the clonal nature of the plasma cells, which can be established by immunostaining for kappa and lambda light chains or by flow cytometry. Typically, plasma cells in solitary plasmacytoma will be positive for CD138, CD38, and show light chain restriction (ie, stain positive for either kappa or lambda but not both). Distinction between solitary plasmacytoma and multiple myeloma or other closely related plasma cell tumors (eg, Waldenström macroglobulinemia) requires additional studies as noted below.</p><p class="headingAnchor" id="H7"><span class="h2">Multiple myeloma</span><span class="headingEndMark"> — </span>SEP is composed of plasma cells that are histologically and immunophenotypically identical to those seen in multiple myeloma; however, the treatment of these two entities differs significantly, necessitating a careful review of the diagnosis. A distinction between these two conditions is made based on the exclusion of additional lesions in patients with SEP. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p>As mentioned above, the diagnosis of SEP requires the exclusion of features of multiple myeloma as evidenced by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Normal bone marrow with no evidence of clonal plasma cells. Patients with an apparent SEP who have clonal involvement of the marrow &lt;10 percent are considered to have SEP with minimal marrow involvement. Patients with an apparent SEP and 10 percent or more clonal plasma cells detected in the bone marrow aspirate or biopsy and/or involved:uninvolved serum free light chain (FLC) ratio ≥100 meet the criteria for multiple myeloma [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><sup>18</sup>F-FDG PET/CT is negative for evidence of multiple myeloma (except for the primary solitary lesion).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of lytic lesions, anemia, hypercalcemia, and kidney impairment, unless these are due to a cause other than a plasma cell dyscrasia.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Waldenström macroglobulinemia</span><span class="headingEndMark"> — </span>Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity demonstrating lymphoplasmacytic lymphoma (LPL) in the bone marrow and/or lymphatic tissue with an IgM monoclonal gammopathy in the blood. Patients may present with symptoms related to the infiltration of the hematopoietic tissues or the effects of monoclonal IgM in the blood. In comparison, patients with SEP will have no clonal lymphoplasmacytic cells on bone marrow biopsy and only rarely have an unrelated IgM monoclonal gammopathy. (See  <a class="medical medical_review" href="/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of choice for SEP is radiation therapy (RT) given with curative intent at a dose of 40 to 50 Gy over a four week period [<a href="#rid13">13,26-28</a>]. If a complete surgical resection was performed as part of the diagnosis, the role of adjuvant RT is less clear. Small lesions may be cured with surgery alone, and no adjuvant RT is indicated unless there is suspicion of residual local disease. Adjuvant chemotherapy does not appear to improve relapse rate or increase disease-free survival [<a href="#rid6">6</a>]. Osteoclast inhibitors (eg, bisphosphonates) are not recommended for patients with SEP, except in the setting of underlying osteopenia. (See  <a class="medical medical_review" href="/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors", section on 'Indications'</a>.)</p><p>For patients with incompletely resected SEP, we recommend the use of local RT rather than further surgery, chemotherapy, or observation. For patients with completely resected SEP after diagnostic biopsy, we suggest observation rather than adjuvant RT or chemotherapy, although other experts may reasonably offer adjuvant RT in this setting. This approach is based on retrospective analyses [<a href="#rid13">13,26,29,30</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective single institution analysis of 18 consecutive patients who received RT (median dose 50 Gy) for SEP of the head and neck reported no recurrences in the radiation field [<a href="#rid26">26</a>]. There was a marginal recurrence that was treated successfully with another course of RT. At a median follow-up of 6.8 years, six patients experienced disease progression to multiple myeloma (two patients) or developed plasmacytoma at another site (four patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second retrospective single institution analysis of 25 consecutive patients who received RT (median dose 45 Gy) for SEP reported local recurrence in five patients (one marginal and four in-field) [<a href="#rid29">29</a>]. At a median follow-up of 64 months, the five-year probability of progression to myeloma was 30 percent and the five-year overall survival rate was 85 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of 5056 patients with solitary plasmacytoma, including 1528 patients with SEP, treatment with both radiation and surgery resulted in superior overall survival than use of either modality alone [<a href="#rid13">13</a>]. In addition, those treated with a radiation dose &lt;40 Gy had worse overall survival on multivariable analysis. Since treatment differed significantly by site of involvement, it is not known whether these survival differences are due to treatment given, site involved, or a combination of the two.</p><p></p><p>The ideal dose of radiation in this setting is unknown. Retrospective analyses have suggested that radiation doses of 40 Gy or greater are associated with improved local control (eg, local failure rates of 9 versus 23 percent) [<a href="#rid7">7,13,26</a>].</p><p>There are limited data regarding the preferred radiation volume for SEP. A retrospective study of patients with SEP of the head and neck suggested an increased risk of recurrence when RT was administered to the gross tumor plus a 2 cm margin when compared with those who received RT to the entire nasal cavity or paranasal sinuses [<a href="#rid26">26</a>]. However, with improved imaging, recurrence rates without nodal radiation are very low (approximately 5 percent), and elective lymph node coverage is not recommended for SEP [<a href="#rid28">28</a>].</p><p>As mentioned above, the role of RT after a complete surgical resection is less clear with some series suggesting improved median survival rates when adjuvant RT is used [<a href="#rid8">8</a>] and others suggesting no difference in outcomes [<a href="#rid9">9</a>]. Given the lack of proven benefit and potential for RT-associated complications, including radiation-induced second malignancies, we reserve adjuvant RT for patients with suspected local residual disease.</p><p class="headingAnchor" id="H11"><span class="h1">RESPONSE ASSESSMENT AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depend on the comfort of both the patient and physician. If the SEP was measurable by an imaging modality prior to therapy, the same modality (eg, <sup>18</sup>F-FDG PET/CT) should be repeated three to four months after completing therapy, and periodically thereafter.</p><p>In general, we see patients every three months for the first two years, then every six months for an additional three years, then yearly or every other year after five years. At these visits we perform a history and physical examination, urine and serum protein electrophoresis with immunofixation, free light chain (FLC) assay, complete blood count, serum creatinine, and serum calcium. For patients with head and neck involvement, we also perform a fiberoptic endoscopy every 6 to 12 months for the first five years after treatment. All patients undergo <sup>18</sup>F-FDG PET/CT or MRI (whichever imaging modality was used for the initial evaluation) every 6 to 12 months for the first five years after therapy. Other follow-up imaging depends on the original tumor site.</p><p>There are no guidelines for the assessment of treatment response in SEP, and practice varies. We agree with an approach proposed by a European expert panel, which combines response evaluation criteria in solid tumors (RECIST) with the International Myeloma Working Group (IMWG) response criteria for multiple myeloma (MM)  (<a class="graphic graphic_table graphicRef140707" href="/d/graphic/140707.html" rel="external">table 2</a>) [<a href="#rid23">23,31,32</a>]. RECIST is used to evaluate the extramedullary tumor while the IMWG response criteria are used to evaluate the monoclonal protein.</p><p>When present, the serum monoclonal protein can remain stable for several months before declining. If serum monoclonal protein levels increase or if the patient develops signs of myeloma-associated end-organ damage, obtain a new bone marrow sample and perform other diagnostic testing (eg, imaging) to determine if the patient has experienced progression to myeloma.</p><p>It is preferable to use the same imaging technique for diagnosis and treatment response assessment [<a href="#rid23">23,31</a>]. PET/CT is usually preferred over MRI given its superior sensitivity [<a href="#rid33">33</a>].A persistent high uptake on <sup>18</sup>F-FDG PET/CT indicates the presence of residual disease.</p><p class="headingAnchor" id="H1102073839"><span class="h1">RELAPSED OR REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>There is no consensus about the treatment of relapsed or refractory SEP because of the high cure rates following surgery or radiation therapy (RT) and limited data to guide management. At the time of relapse, a full repeat diagnostic evaluation (with a new biopsy of the lesion) is required to confirm the clonal plasma cell infiltration and exclude other plasma cell disorders. (See <a class="local">'Evaluation'</a> above.)</p><p>If the evaluation at relapse reveals a myeloma-defining event (eg, end-organ damage or a biomarker for myeloma), SEP has evolved to multiple myeloma (MM) and systemic therapy for MM is appropriate. (See  <a class="medical medical_review" href="/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment"</a>.)</p><p>If there are no myeloma-defining events, management of local relapse is individualized based on the prior therapy with the following considerations (see <a class="local">'Treatment'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>A lesion that recurs in the same location following surgery alone can be treated with RT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lesion that recurs in the same location following RT may be amenable to surgical resection or additional RT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A decision regarding retreatment with either surgery or RT is influenced by the patient's symptoms, prior RT dose, tumor location, and timing of relapse.</p><p></p><p>If relapse occurs at a different location, there should be a high suspicion for systemic disease (ie, multiple myeloma). Following a careful evaluation to rule out systemic disease, management is highly individualized and may include RT, surgical resection, and/or systemic therapy.</p><p class="headingAnchor" id="H4026649512"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Less than 7 percent of patients with SEP will develop a local recurrence after tumoricidal radiation [<a href="#rid27">27,34</a>]. Approximately 10 to 15 percent of patients will ultimately develop multiple myeloma [<a href="#rid35">35,36</a>]. The progression rate is higher (20 percent) in patients with SEP with minimal marrow involvement. </p><p>Reported five-year overall survival rates for patients with SEP have ranged from 40 to 85 percent [<a href="#rid9">9,37-40</a>]. It is unknown if tumor location affects outcome. Initial reports suggest that involvement of the head and neck may portend a better prognosis, while connective/soft tissue lesions may portend a worse prognosis. However, it is unclear whether differences in management can account for these different outcomes. In a retrospective analysis that included 1528 patients with SEP, the median overall survival was 11 years the population overall, 6.8 years for the 295 patients with connective/soft tissue involvement, and not reached for the 681 patients with head and neck involvement [<a href="#rid13">13</a>]. In another series of 18 patients with SEP of the head and neck treated at the Mayo Clinic, the median overall survival was 12.5 years with five- and 10-year survival rates of 88 and 55 percent, respectively [<a href="#rid26">26</a>]. Six patients developed multiple myeloma or plasmacytoma at a distant site. In addition, an analysis of the Surveillance, Epidemiology, and End Results (SEER) database that included 1185 patients with extramedullary plasmacytoma reported superior median survival among patients with involvement of the head and neck when compared with patients with other sites of extramedullary plasmacytoma (13 versus 4 years) [<a href="#rid12">12</a>]. Patients with involvement of the head and neck were less likely to be treated with surgery alone and more likely to have combined modality treatment with surgery and radiation therapy.</p><p class="headingAnchor" id="H3500137833"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a> and  <a class="medical medical_society_guidelines" href="/d/html/121241.html" rel="external">"Society guideline links: Solitary plasmacytoma"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Solitary extramedullary plasmacytomas (SEP) are plasma cell tumors that arise outside of the bone marrow. Most patients present with symptoms related to the location of the mass, which are most frequently located in the head and neck region. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The evaluation of a patient with a suspected SEP should include a biopsy of the suspected lesion, a unilateral bone marrow aspirate and biopsy, and laboratory studies. Imaging should include a fluorine-18-labeled fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) scan. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of an SEP requires the following  (<a class="graphic graphic_table graphicRef98065" href="/d/graphic/98065.html" rel="external">table 1</a>) (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Biopsy-proven extramedullary tumor with evidence of clonal plasma cells.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><sup>18</sup>F-FDG PET/CT must show no lytic or extramedullary lesions (except for the primary solitary lesion).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow aspirate and biopsy demonstrates &lt;10 percent clonal plasma cells. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no anemia, hypercalcemia, or kidney impairment that could be attributed to a clonal plasma cell proliferative disorder.</p><p></p><p class="bulletIndent1">The presence of clonal plasma cells (&lt;10 percent) in the bone marrow is considered solitary plasmacytoma with minimal marrow involvement. Presence of ≥10 percent clonal bone marrow plasma cells in a patient with SEP will automatically meet required criteria for multiple myeloma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The treatment of SEP depends primarily on whether the diagnostic biopsy was a complete or incomplete resection of the tumor:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an incompletely resected SEP after diagnostic biopsy, we recommend the use of local radiation therapy rather than further surgery, chemotherapy, or observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with completely resected SEP after diagnostic biopsy, we suggest observation rather than adjuvant radiation therapy or chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Other experts may reasonably offer adjuvant radiation therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for osteoclast inhibitors</strong> – Osteoclast inhibitors (eg, bisphosphonates) are not routinely used for patients with SEP, except in the setting of underlying osteopenia. (See  <a class="medical medical_review" href="/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors", section on 'Indications'</a>.)</p><p></p><p class="headingAnchor" id="H2553111728"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges the extensive contributions of Robert A Kyle, MD to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001.</li><li><a class="nounderline abstract_t">Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004; 124:717.</a></li><li class="breakAll">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Hughes M, Doig A, Soutar R. Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns. Br J Haematol 2007; 137:486.</a></li><li><a class="nounderline abstract_t">Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 2009; 144:86.</a></li><li><a class="nounderline abstract_t">Shih LY, Dunn P, Leung WM, et al. Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 1995; 71:128.</a></li><li><a class="nounderline abstract_t">Pavithran K, Doval DC, Rao CR, et al. Pediatric solitary plasmacytoma. Acta Oncol 1997; 36:83.</a></li><li><a class="nounderline abstract_t">Boos N, Goytan M, Fraser R, Aebi M. Solitary plasma-cell myeloma of the spine in an adolescent. Case report of an unusual presentation. J Bone Joint Surg Br 1997; 79:812.</a></li><li><a class="nounderline abstract_t">Bataille R, Sany J. Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer 1981; 48:845.</a></li><li><a class="nounderline abstract_t">International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.</a></li><li><a class="nounderline abstract_t">Gerry D, Lentsch EJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg 2013; 148:974.</a></li><li><a class="nounderline abstract_t">Goyal G, Bartley AC, Funni S, et al. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia 2018; 32:1414.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81:693.</a></li><li><a class="nounderline abstract_t">Mayr NA, Wen BC, Hussey DH, et al. The role of radiation therapy in the treatment of solitary plasmacytomas. Radiother Oncol 1990; 17:293.</a></li><li><a class="nounderline abstract_t">Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer 1992; 69:1513.</a></li><li><a class="nounderline abstract_t">Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 2001; 50:113.</a></li><li><a class="nounderline abstract_t">Anghel G, Petti N, Remotti D, et al. Testicular plasmacytoma: report of a case and review of the literature. Am J Hematol 2002; 71:98.</a></li><li><a class="nounderline abstract_t">McCormack S, Hamad E, Hamad A. Solitary Plasmacytoma of the Breast: A Case of an Uncommon Breast Neoplasm. Case Rep Hematol 2023; 2023:9622042.</a></li><li><a class="nounderline abstract_t">Bolek TW, Marcus RB Jr, Mendenhall NP. Solitary plasmacytoma of bone and soft tissue. Int J Radiat Oncol Biol Phys 1996; 36:329.</a></li><li><a class="nounderline abstract_t">Galieni P, Cavo M, Avvisati G, et al. Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities? Ann Oncol 1995; 6:687.</a></li><li><a class="nounderline abstract_t">Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019; 20:e302.</a></li><li><a class="nounderline abstract_t">Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018; 11:10.</a></li><li><a class="nounderline abstract_t">Tirumani SH, Shinagare AB, Jagannathan JP, et al. MRI features of extramedullary myeloma. AJR Am J Roentgenol 2014; 202:803.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</a></li><li><a class="nounderline abstract_t">Creach KM, Foote RL, Neben-Wittich MA, Kyle RA. Radiotherapy for extramedullary plasmacytoma of the head and neck. Int J Radiat Oncol Biol Phys 2009; 73:789.</a></li><li><a class="nounderline abstract_t">Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys 2006; 64:1013.</a></li><li><a class="nounderline abstract_t">Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018; 101:794.</a></li><li><a class="nounderline abstract_t">Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 2011; 117:4468.</a></li><li><a class="nounderline abstract_t">Curry J, O'steen L, Morris CG, et al. Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma. Am J Clin Oncol 2020; 43:709.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.</a></li><li><a class="nounderline abstract_t">Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17:e328.</a></li><li><a class="nounderline abstract_t">Fouquet G, Guidez S, Herbaux C, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res 2014; 20:3254.</a></li><li><a class="nounderline abstract_t">Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 2006; 64:210.</a></li><li><a class="nounderline abstract_t">de Waal EG, Leene M, Veeger N, et al. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. Br J Haematol 2016; 175:661.</a></li><li><a class="nounderline abstract_t">Katodritou E, Terpos E, Symeonidis AS, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol 2014; 89:803.</a></li><li><a class="nounderline abstract_t">Avilés A, Huerta-Guzmán J, Delgado S, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol 1996; 14:111.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Goldstein J, Fuller L, et al. Curability of solitary bone plasmacytoma. J Clin Oncol 1992; 10:587.</a></li><li><a class="nounderline abstract_t">Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1983; 1:255.</a></li><li><a class="nounderline abstract_t">Finsinger P, Grammatico S, Chisini M, et al. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol 2016; 172:554.</a></li></ol></div><div id="topicVersionRevision">Topic 6659 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009059" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009059" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428237" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7819027" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090974" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pediatric solitary plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9331042" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Solitary plasma-cell myeloma of the spine in an adolescent. Case report of an unusual presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7248911" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Solitary myeloma: clinical and prognostic features of a review of 114 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780789" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23482476" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654264" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16706268" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2343147" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of radiation therapy in the treatment of solitary plasmacytomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1540888" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Plasmacytoma. Treatment results and conversion to myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316553" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Testicular plasmacytoma: report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37303483" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Solitary Plasmacytoma of the Breast: A Case of an Uncommon Breast Neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892456" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Solitary plasmacytoma of bone and soft tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664190" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different entities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29338789" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24660710" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : MRI features of extramedullary myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18707826" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Radiotherapy for extramedullary plasmacytoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343803" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: A dose greater than 45 Gy to the target volume improves the local control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976492" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21437886" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32739971" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27511158" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714772" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16229966" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27605358" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757085" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9119355" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Improved outcome in solitary bone plasmacytomata with combined therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548521" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Curability of solitary bone plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6668499" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684545" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical features and prognostic factors in solitary plasmacytoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
